Active — Not RecruitingNot Applicable

A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.

Japan50 participantsStarted 2025-10-30

Plain-language summary

A study to evaluate the safety of Hympavzi under the actual use in patients with congenital hemophilia who do not have inhibitors.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: * Patients who have received at least one dose of this drug after the launch of this drug

What they're measuring

Number of the participants with adverse drug reactions

Timeframe: The evaluation period is from the first dose of Himpavzi up to 156 weeks (3 years).

Trial details

NCT IDNCT07161687

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2030-04-11

View on ClinicalTrials.gov More Hemophilia A or B trials